FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
9 letters match. Newest first.
-
BiologicsNexCell Scientific Inc
NexCell Scientific markets an unapproved, unlicensed umbilical cord blood cell product with serious manufacturing violations.
High risk -
DrugsJabil Inc.
FDA warned Jabil Inc. after an inspection found inadequate investigations of mold and sterility failures at its sterile injectable contract manufacturer.
High risk -
DrugsExcelvision - Fareva
FDA warned Excelvision-Fareva after a 2026 inspection found inadequate contamination investigations and aseptic failures for sterile drugs.
High risk -
DrugsHuons Co., Ltd.
FDA cites Huons in South Korea for data integrity and sterility failures in drug manufacturing.
High risk -
DrugsPharmathen International S.A.
FDA warns Pharmathen over inadequate aseptic controls at its Greek plant making sterile drugs for the U.S.
High risk -
DrugsUCSF Radiopharmaceutical Facility
FDA cited UCSF Radiopharmaceutical Facility for inadequate sterility failure investigations and environmental monitoring of sterile drug manufacturing.
High risk -
DrugsBoothwyn Pharmacy, LLC
Boothwyn Pharmacy made sterile drugs in insanitary conditions and shipped lots that failed sterility and potency tests.
High risk -
DrugsOasis Medical, Inc.
FDA cites Oasis Medical for current good manufacturing practice violations in sterile ophthalmic drugs, including particulate contamination and unresolved sterility failures.
High risk -
DrugsApothecary Health Solutions/Right Value Drug Stores, LLC dba Carie Boyd's Prescription Shop
FDA cited Carie Boyd's Prescription Shop for compounded drugs that failed outsourcing-facility labeling and reporting rules.
Medium